BRPI0922303A2 - arilciclo-hexiléteres de di-hidrotetra-azabenzoazulenos para o uso como antagonistas do receptor de vasopressina v1a - Google Patents

arilciclo-hexiléteres de di-hidrotetra-azabenzoazulenos para o uso como antagonistas do receptor de vasopressina v1a

Info

Publication number
BRPI0922303A2
BRPI0922303A2 BRPI0922303A BRPI0922303A BRPI0922303A2 BR PI0922303 A2 BRPI0922303 A2 BR PI0922303A2 BR PI0922303 A BRPI0922303 A BR PI0922303A BR PI0922303 A BRPI0922303 A BR PI0922303A BR PI0922303 A2 BRPI0922303 A2 BR PI0922303A2
Authority
BR
Brazil
Prior art keywords
dihydrotetraazabenzoazulenes
arylcyclohexylethers
receptor antagonists
vasopressin receptor
vasopressin
Prior art date
Application number
BRPI0922303A
Other languages
English (en)
Inventor
Patrick Schnider
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0922303A2 publication Critical patent/BRPI0922303A2/pt
Publication of BRPI0922303B1 publication Critical patent/BRPI0922303B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
BRPI0922303-7A 2008-11-28 2009-11-18 arilciclo-hexiléteres de di-hidrotetra-azabenzoazulenos, seu processo de preparação, composição farmacêutica que os compreende e uso BRPI0922303B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08170188 2008-11-28
PCT/EP2009/065354 WO2010060836A1 (en) 2008-11-28 2009-11-18 Arylcyclohexylethers of dihydrotetraazabenzoazulenes for use as vasopressin via receptor antagonists

Publications (2)

Publication Number Publication Date
BRPI0922303A2 true BRPI0922303A2 (pt) 2016-01-12
BRPI0922303B1 BRPI0922303B1 (pt) 2019-11-12

Family

ID=41382009

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0922303-7A BRPI0922303B1 (pt) 2008-11-28 2009-11-18 arilciclo-hexiléteres de di-hidrotetra-azabenzoazulenos, seu processo de preparação, composição farmacêutica que os compreende e uso

Country Status (31)

Country Link
US (2) US8227458B2 (pt)
EP (1) EP2370441B1 (pt)
JP (1) JP5452608B2 (pt)
KR (1) KR101359742B1 (pt)
CN (1) CN102227428B (pt)
AR (2) AR074409A1 (pt)
AU (1) AU2009319123B2 (pt)
BR (1) BRPI0922303B1 (pt)
CA (1) CA2743976C (pt)
CO (1) CO6341478A2 (pt)
CR (1) CR20110220A (pt)
CY (1) CY1115435T1 (pt)
DK (1) DK2370441T3 (pt)
EC (1) ECSP11011089A (pt)
ES (1) ES2431279T3 (pt)
HR (1) HRP20131067T1 (pt)
IL (1) IL212122A (pt)
MA (1) MA32781B1 (pt)
MX (1) MX2011005596A (pt)
MY (1) MY150837A (pt)
NZ (1) NZ592076A (pt)
PE (1) PE20110582A1 (pt)
PL (1) PL2370441T3 (pt)
PT (1) PT2370441E (pt)
RU (1) RU2507205C2 (pt)
SG (1) SG171846A1 (pt)
SI (1) SI2370441T1 (pt)
TW (1) TWI379833B (pt)
UA (1) UA103504C2 (pt)
WO (1) WO2010060836A1 (pt)
ZA (1) ZA201103419B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8952037B2 (en) 2010-05-13 2015-02-10 Amgen Inc. Heteroaryloxycarbocyclyl compounds as PDE10 inhibitors
US8828989B2 (en) * 2011-09-26 2014-09-09 Hoffmann-La Roche Inc. Oxy-cyclohexyl-4H,6H-5-oxa-2,3,10b-triaza-benzo[E]azulenes as V1A antagonists
CA2847095A1 (en) * 2011-10-05 2013-04-11 F. Hoffmann-La Roche Ag Cyclohexyl-4h,6h-5-oxa-2,3,10b-triaza-benzo[e]azulenes as v1a antagonists
CN105492010B (zh) * 2013-08-19 2020-01-03 豪夫迈·罗氏有限公司 用于治疗相移睡眠障碍的V1a拮抗剂
HRP20210966T1 (hr) 2013-12-05 2021-09-17 F. Hoffmann - La Roche Ag Sinteza trans-8-kloro-5-metil-1-[4-(piridin-2-iloksi)-cikloheksil]-5,6-dihidro-4h-2,3,5,10b-tetraaza­benzo[e]azulena i njegovih kristalnih oblika
WO2017191117A1 (en) 2016-05-03 2017-11-09 Bayer Pharma Aktiengesellschaft V1a receptor antagonists for use in the treatment of renal diseases
RU2666598C1 (ru) * 2017-07-14 2018-09-11 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" Средство для коррекции расстройств аутистического спектра
US11033601B2 (en) 2017-09-14 2021-06-15 The Regents Of The University Of Colorado, A Body Corporate Selective inhibition of V1b for treating fatty liver
MX2020004105A (es) * 2017-12-08 2020-09-22 Hoffmann La Roche Formulacion farmaceutica.
TW201938171A (zh) 2017-12-15 2019-10-01 匈牙利商羅特格登公司 作為血管升壓素Ｖ１ａ受體拮抗劑之三環化合物
HU231206B1 (hu) 2017-12-15 2021-10-28 Richter Gedeon Nyrt. Triazolobenzazepinek
WO2020139670A1 (en) 2018-12-27 2020-07-02 Teva Pharmaceuticals International Gmbh Solid state forms of balovaptan
WO2022018121A1 (en) * 2020-07-23 2022-01-27 F. Hoffmann-La Roche Ag Cyclohexyl substituted triazoles as vasopressin receptor v1 a antagonists

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521173A (en) 1995-01-17 1996-05-28 American Home Products Corporation Tricyclic benzazepine vasopressin antagonists
TR200102069T2 (tr) 1999-01-19 2001-11-21 Ortho-Mcneil Pharmaceutical, Inc. Vasopresin reseptörü antagonistleri olarak trisiklik benzodiazepinler.
TWI239333B (en) * 2000-11-16 2005-09-11 Hoffmann La Roche Benzodiazepine derivatives as GABA A receptor modulators
US7022699B2 (en) 2001-04-12 2006-04-04 Wyeth Cyclohexenyl phenyl diazepines vasopressin and oxytocin receptor modulators
GB0303852D0 (en) 2003-02-19 2003-03-26 Pfizer Ltd Triazole compounds useful in therapy
GB0400700D0 (en) * 2004-01-13 2004-02-18 Pfizer Ltd Compounds useful in therapy
GEP20094723B (en) 2004-05-25 2009-07-10 Pfizer Prod Inc Tetraazabenzo [e] azulene derivatives and analogs thereof
KR100840852B1 (ko) 2004-05-25 2008-06-23 화이자 프로덕츠 인크. 테트라아자벤조[ｅ]아줄렌 유도체 및 이의 유사체
EP1632494A1 (en) 2004-08-24 2006-03-08 Ferring B.V. Vasopressin v1a antagonists
BRPI0514458A (pt) 2004-08-25 2008-06-10 Pfizer triazolbenzodiazepinas e seu uso como antagonistas de vasopressina
JP2008539220A (ja) 2005-04-26 2008-11-13 ファイザー・リミテッド バソプレシンアンタゴニストとしてのトリアゾール誘導体
EP1885713A1 (en) 2005-05-18 2008-02-13 Pfizer Limited 1, 2, 4 -triazole derivatives as vasopressin antagonists
WO2008084005A1 (en) 2007-01-12 2008-07-17 F. Hoffmann-La Roche Ag Spiropiperidine glycinamide derivatives
WO2009125800A1 (ja) * 2008-04-09 2009-10-15 株式会社クラレ ガスバリア性積層体およびその製造方法
AU2009315754B2 (en) 2008-11-13 2013-08-15 F. Hoffmann-La Roche Ag Spiro-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulenes
PE20110590A1 (es) 2008-11-18 2011-08-31 Hoffmann La Roche Alquilciclohexileteres de dihidrotetraazabenzoazulenos
US8420633B2 (en) 2010-03-31 2013-04-16 Hoffmann-La Roche Inc. Aryl-cyclohexyl-tetraazabenzo[e]azulenes
US8461151B2 (en) 2010-04-13 2013-06-11 Hoffmann-La Roche Inc. Aryl-/heteroaryl-cyclohexenyl-tetraazabenzo[e]azulenes
US8492376B2 (en) 2010-04-21 2013-07-23 Hoffmann-La Roche Inc. Heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes
US8481528B2 (en) 2010-04-26 2013-07-09 Hoffmann-La Roche Inc. Heterobiaryl-cyclohexyl-tetraazabenzo[e]azulenes
US8513238B2 (en) 2010-05-10 2013-08-20 Hoffmann-La Roche Inc. Heteroaryl-cyclohexyl-tetraazabenzo[E]azulenes

Also Published As

Publication number Publication date
RU2507205C2 (ru) 2014-02-20
DK2370441T3 (da) 2013-10-21
CN102227428A (zh) 2011-10-26
US20120225865A1 (en) 2012-09-06
MX2011005596A (es) 2011-06-16
MY150837A (en) 2014-02-28
JP5452608B2 (ja) 2014-03-26
ZA201103419B (en) 2014-07-30
HK1160642A1 (en) 2012-08-10
SI2370441T1 (sl) 2013-12-31
AU2009319123B2 (en) 2014-10-23
SG171846A1 (en) 2011-07-28
US8227458B2 (en) 2012-07-24
PL2370441T3 (pl) 2014-02-28
UA103504C2 (ru) 2013-10-25
TW201024300A (en) 2010-07-01
HRP20131067T1 (hr) 2013-12-06
CA2743976A1 (en) 2010-06-03
US20100137286A1 (en) 2010-06-03
WO2010060836A1 (en) 2010-06-03
JP2012510441A (ja) 2012-05-10
ECSP11011089A (es) 2011-06-30
RU2011123703A (ru) 2013-01-10
AR074409A1 (es) 2011-01-12
CY1115435T1 (el) 2017-01-04
CA2743976C (en) 2017-02-21
AR112338A2 (es) 2019-10-16
EP2370441A1 (en) 2011-10-05
IL212122A0 (en) 2011-06-30
BRPI0922303B1 (pt) 2019-11-12
KR101359742B1 (ko) 2014-02-06
ES2431279T3 (es) 2013-11-25
PT2370441E (pt) 2013-11-14
CN102227428B (zh) 2015-03-25
MA32781B1 (fr) 2011-11-01
PE20110582A1 (es) 2011-08-17
CO6341478A2 (es) 2011-11-21
NZ592076A (en) 2012-06-29
CR20110220A (es) 2011-06-21
IL212122A (en) 2013-06-27
KR20110077022A (ko) 2011-07-06
AU2009319123A1 (en) 2010-06-03
US8461152B2 (en) 2013-06-11
TWI379833B (en) 2012-12-21
EP2370441B1 (en) 2013-09-11

Similar Documents

Publication Publication Date Title
HUS2200033I1 (hu) CGRP receptor antagonisták
BRPI0913930A2 (pt) antagonistas de receptores de prostaglandinas d2
DK2501703T3 (da) Spiropiperidinforbindelser som orl-1-receptorantagonister
BRPI0919844A2 (pt) compostos de azaindazol como antagonistas do receptor ccr1
EP2350060A4 (en) Melanocortin receptor AGONISTS
BRPI0923512A2 (pt) antagonistas de receptores de ácido lisofosfatídico
BRPI0821141A2 (pt) Derivados de heteroarila como antagonistas do receptor de orexina
BRPI1014572A2 (pt) imidazoprazinas para uso como inibidores de cinase
DK2501704T3 (da) Spiropiperidinforbindelser som oral-1-receptorantagonister
BRPI0911563A2 (pt) uso de antagonista da progesterona
BRPI0813768A2 (pt) Derivados de benzazepina úteis como antagonistas de vasopressina
BRPI0909157A2 (pt) compostos heterocíclicos como antagonistas de receptores de adenosina
BRPI0717023A2 (pt) Tiazol pirazolopirimidina como antagonistas do receptor de crf1
DK2821407T3 (da) Piperidinoncarboxamidazaindan-cgrp receptorantagonister
BRPI0910118A2 (pt) antagonistas de receptores do glucagon
BRPI0717937A2 (pt) Compostos de pirazona como antagonistas do receptor mineralocorticóide
BRPI0907364A2 (pt) Antagonistas aminoalquilbifenil n,n-disubstituídos de receptores d2 de prostaglandina
EP2362779A4 (en) CXCR4 RECEPTOR COMPOUNDS
DK2252581T3 (da) Kappa-selektiv opioidreceptorantagonist
BRPI1015367A2 (pt) imidazotiodiazois para uso como inibidores de cinase
ATE519738T1 (de) Pyrrolidinarylether als nk3-rezeptorantagonisten
ATE517100T1 (de) Pyrrolidinarylether als nk3-rezeptorantagonisten
PL2370441T3 (pl) Arylocykloheksyloetery dihydrotetraazabenzoazulenów do stosowania jako antagoniści receptora v1a wazopresyny
BRPI0817061A2 (pt) Derivados de pirrolidinilalquilisoquinolinona e -isoindolinona como antagonistas de histamina-3
BRPI0814767A2 (pt) Derivados de monoamida como antagonistas do receptor de orexina

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/11/2009, OBSERVADAS AS CONDICOES LEGAIS. (CO) 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/11/2009, OBSERVADAS AS CONDICOES LEGAIS